Logo Home   About us   Clinical trial   R&D   Diagnostics   Investors   News   In press   Contact us
News & Events



2014-04-01
InDex Pharmaceuticals and Almirall enter into a license agreement for European rights of the phase III drug candidate Kappaproct® Read more...
InDex Pharmaceuticals och Almirall ingår licensavtal för de europeiska rättigheterna till fas III-läkemedelskandidaten Kappaproct® Läs mer...


2014-02-25
InDex Pharmaceuticals closes $20 m financing round and welcomes NeoMed as new shareholder. Read more...
InDex Pharmaceuticals slutför finansieringsrunda om USD 20 m (EUR 15 m) och välkomnar NeoMed som ny aktieägare. Läs mer...


2013-04-08
InDex Pharmaceuticals reports completion of patient recruitment in Phase III Ulcerative Colitis Study (COLLECT) with Kappaproct. Read more...
InDex Pharmaceuticals meddelar slutförandet av patientrekrytering i fas III ulcerös kolit studie (COLLECT) med Kappaproct. Läs mer...


2012-10-24
InDex Pharmaceuticals Granted Japanese Patent for Novel Treatment of Steroid-Resistant Inflammation. Read more...
InDex Pharmaceuticals beviljas japanskt patent för ny behandling av steroidresistent inflammation. Läs mer...


2012-08-30
InDex Pharmaceuticals Strengthens IP Position for Kappaproct. Read more...
InDex Pharmaceuticals utökar patentportföljen för läkemedelskandidaten Kappaproct. Läs mer...


2012-07-09
InDex publish positive results from Kappaproct Compassionate Use program. Click for article


2012-06-19
Kappaproct Drastically Reduces the Need for Colectomy in Patients with Severe Ulcerative Colitis. Read more...
Kappaproct minskar behovet av kirurgiskt ingrepp för patienter med svår ulcerös kolit. Läs mer...


2012-05-29
InDex Pharmaceuticals Appoints Stig Løkke Pedersen as Board Member. Read more...
InDex Pharmaceuticals utser Stig Løkke Pedersen Pedersen till styrelseledamot. Läs mer...


2012-04-26
InDex Pharmaceuticals Granted US Patent for Novel Treatment of Steroid-Resistant Inflammation. Read more...
InDex Pharmaceuticals beviljas amerikanskt patent för ny behandling av steroidresistent inflammation. Läs mer...


2012-04-11
InDex Pharmaceuticals Expands Management Team. Read more...
InDex Pharmaceuticals utökar ledningsgruppen. Läs mer...


2012-03-20
InDex Pharmaceuticals develops companion diagnostic test for new ulcerative colitis therapy. Read more...
InDex Pharmaceuticals utvecklar companion diagnostics för ny ulcerös kolit behandling. Läs mer...


2012-03-06
InDex Pharmaceuticals Starts Phase III COLLECT Study with Kappaproct®. Read more...
InDex Pharmaceuticals startar fas III studien COLLECT för Kappaproct®. Läs mer...


2011-10-24
InDex Pharmaceuticals participates at the UEGW (19th United European Gastroenterology Week) at Stockholmsmässan Oct 24-26.


2011-07-07
InDex Pharmaceuticals names Jesper Wiklund Chief Executive Officer. Read more...


2011-05-17
InDex Pharmaceuticals participates in the Swedish Congress Svenska Gastrodagarna in Umeå May 17-20, 2011.


2011-01-21
InDex Pharmaceuticals completes SEK 75m finance round. Read more...


2010-05-17
Index Pharmaceuticals is present with a booth in the yearly congress Svenska Gatrodagarna in Stockholm 17-20 May, 2010.


2009-12-08
Stockholms läns landsting introduces diagnostic test for patients with inflammatory bowel disease. Read more...


2009-11-11
Patent for the diagnostic test DiBiCol granted in Japan. Read more...


2009-05-18
Based on positive Phase II Results InDex Pharmaceuticals terminates Kappaproct study in advance. Read more...


2009-03-19
Last patient recruited in a Phase II study of Kappaproct. Read more...


2008-11-05
InDex Pharmaceuticals AB has filed five more patents that will further strengthen its extensive portfolio of proprietary intellectual assets. Read more...





InDex Pharmaceuticals AB, Tomtebodavägen 23a, 171 77 Stockholm, Phone: +46 8 508 847 30, Fax: +46 8 508 847 39, info@indexpharma.com
Copyright © 2012 InDex Pharmaceuticals AB. All Rights Reserved.